Evidence map›Paper›PMID 26370551›Full record

ArticleLung2015

Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes.

Michal Shteinberg, Joseph Rivlin, Michal Gur, Muriel Konopnicki, Nili Stein, Michael M Tunney, J Stuart Elborn, Damian G Downey, Elinor Johnston, Hadar Shalom and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Lung, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01806025 (Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01806025 completednot on this map

Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients

TypeobservationalSponsorCarmel Medical CenterRan2013 to 2015Enrolled142ConditionsCystic FibrosisArmsno intervention
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Michal ShteinbergCF Center, Carmel Medical Center, Haifa, Israel. michalsh@tx.technion.ac.il.
Joseph RivlinCF Center, Carmel Medical Center, Haifa, Israel.
Michal GurCF Center, Carmel Medical Center, Haifa, Israel.
Muriel KonopnickiCF Center, Carmel Medical Center, Haifa, Israel.
Nili SteinCF Center, Carmel Medical Center, Haifa, Israel.
Michael M TunneyQueens University Belfast, Belfast, UK.
J Stuart ElbornQueens University Belfast, Belfast, UK.
Damian G DowneyQueens University Belfast, Belfast, UK.
Elinor JohnstonQueens University Belfast, Belfast, UK.
Hadar ShalomThe B. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Andrew LevyThe B. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Carmel Medical Center · ILQueen's University Belfast · GBTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haptoglobin (Hp), a heme-Iron chelator, has different isoforms which are associated with variable tendency toward infections: Hp 1-1, Hp 2-1, and Hp 2-2. Cystic fibrosis (CF) outcomes are variable and influenced by genetic and environmental factors. The aim of this study was to determine whether Hp phenotype influenced disease severity in CF. One hundred forty-two CF patients from two centers were analyzed for Haptoglobin phenotype using gel electrophoresis of hemoglobin enriched serum. Clinical and microbiological data including bacterial colonization status, lung function, presence of CF-related diabetes and liver disease, rate of exacerbation, and mortality were compared between Hp phenotype groups. We found a trend toward less mucoid PA among Hp 2-2 (20.4 %) compared with Hp 1-1 and Hp 2-1 individuals (33.3 %), p = 0.317. Hp 2-2 individuals also had less antibiotic courses, and lower inflammatory markers without statistical significance. Haptoglobin phenotype is unlikely to be an important modifier of CF phenotype.

Indexed as

AdolescentAdultAllelesCarrier StateChildCohort StudiesCystic FibrosisDisease ProgressionFemaleForced Expiratory VolumeHaptoglobinsHemoglobinsHeterozygoteHomozygoteHospitalizationHumansHaptoglobinsHemoglobinsHP protein, humanIronCystic fibrosisHaptoglobinPhenotypes

Identifiers

PMID26370551
OpenAlexW1664014950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.